A key opinion leader discusses how the role tucatinib is evolving in the management of HER2-positive metastatic breast cancer.
EP. 1: HER2-Positive mBC Emerging Treatment Landscape
Watch
EP. 2: Currently Accepted Regimens: NCCN Guidelines
EP. 3: HER2CLIMB FDA Approval
EP. 4: R/R HER2+ mBC Management During COVID-19 Pandemic